Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ: UTHR )

356.15 -3.81 (-1.06%)
Streaming Delayed Price Updated: 12:14 PM EST, Dec 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Is Life Sciences Company Miromatrix Medical Stock Trading Higher Today?
United Therapeutics Corporation (NASDAQ: UTHR) has agreed to acquire Miromatrix Medical Inc (NASDAQ: MIRO) for $3.25 per share in cash (an aggregate of approximately $91 million). 
Via Benzinga
Why Is Miromatrix Medical (MIRO) Stock Up 235% Today?
Miromatrix Medical stock is rocketing higher on Monday after the company reached an acquisition agreement with United Therapeutics for MIRO. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage! 
Via InvestorPlace
United Therapeutics to Acquire Miromatrix Medical
From Miromatrix Medical Inc.
Via GlobeNewswire
United Therapeutics: A Strong Quarter But What About 2024?
United Therapeutics had strong Tyvaso sales but it highlights the investor debate heading into 2024. 
Via Talk Markets
What 4 Analyst Ratings Have To Say About United Therapeutics
Via Benzinga
United Therapeutics's Return On Capital Employed Insights
Via Benzinga
United Therapeutics to Acquire Miromatrix Medical
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Third Quarter 2023 Financial Results Before the Market Opens on Wednesday, November 1, 2023
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs
From United Therapeutics Corporation
Via Business Wire
Bullet Proof Your Portfolio: 3 Must-Have Defensive Stocks for 2023
Defensive stocks have always been the go-to investments for those looking to protect their long-term portfolio and weather downturns. 
Via InvestorPlace
The Latest Analyst Ratings for United Therapeutics
Via Benzinga
Why United Therapeutics Shares Are Falling Today
United Therapeutics Corporation's (NASDAQ: UTHR) Q1 revenues grew 10% Y/Y to $506.9 million, missing the  
Via Benzinga
Recap: United Therapeutics Q1 Earnings
Via Benzinga
Analyst Expectations for United Therapeutics's Future
Via Benzinga
United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
This article points you to three undervalued biotech stocks that have the potential to deliver stellar returns for patient investors. 
Via InvestorPlace
United Therapeutics Corporation Reports Second Quarter 2023 Financial Results
From United Therapeutics Corporation
Via Business Wire
This Foreboding Sign Looms Over United Therapeutics's Chart
Via Benzinga
If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names
These are the best biotech stocks that investors can invest in. That's because they are sector leaders that can make you a millionaire. 
Via InvestorPlace
United Therapeutics Corporation to Report Second Quarter 2023 Financial Results Before the Market Opens on Wednesday, August 2, 2023
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Unveils Net Zero Energy Distribution Center
From United Therapeutics Corporation
Via Business Wire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
United Therapeutics Corporation Reports First Quarter 2023 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023
From United Therapeutics Corporation
Via Business Wire
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at Upcoming Scientific Meetings
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.